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OBJECTIVE: Major Salivary gland ultrasonography (SGUS) is widely used for the 
diagnosis of primary Sjögren’s syndrome (pSS). Our objective was to assess the contribution 
of SGUS compared to other items of the 2016 ACR/EULAR pSS classification criteria, 
based on expert opinion. 
METHODS: A secure web-based relational database was used by 24 experts from 14 
countries to assess 512 realistic vignettes developed from data of patients with suspected 
pSS. Each vignette provided classification criteria items and information on history, clinical 
symptoms, and SGUS findings. Each expert assessed 64 vignettes and each vignette was 
assessed by 3 experts. A diagnosis of pSS was defined according to at least 2 of 3 experts. 
Validation was performed in the independent French DiapSS cohort of patients with 
suspected pSS. 
RESULTS: A criteria-based pSS diagnosis and SGUS findings were independently 
associated with an expert diagnosis of pSS (p<0.001) The derived diagnostic weights of 
individual items in the 2016 ACR/EULAR criteria including SGUS were : anti-SSA, 3; 
focus score ≥1, 3; SGUS score ≥2, 1; positive Schirmer’s test, 1; dry mouth, 1; and salivary 
flow rate <0.1 mL/min, 1. The corrected C statistic area under the curve for the new 
weighted score was 0.96.Adding SGUS improve the sensitivity from 90.2 % to 95.6% with a 
quite similar specificity 84.1% versus 82.6%. Results were similar in the DiapSS cohort: 
adding SGUS improve the sensitivity from 87% to 93%.  
CONCLUSION: SGUS had similar weight compared to minor items and its addition 





Lymphocytic infiltration of the salivary glands (SGs) is a key pathologic feature of 
primary Sjögren’s syndrome (pSS) (1, 2). Currently available tools for assessing the SGs 
include salivary flow measurement, minor labial salivary gland (LSG) biopsy (3, 4), 
sialography, and scintigraphy (5). In addition, salivary gland ultrasonography (SGUS) holds 
considerable appeal (6), as it is non-invasive, non-irradiating, and can be repeated as an 
outpatient investigation (7-9). Many researchers and clinicians have identified SGUS as a 
valuable diagnostic tool and potential criteria item for disease classification of pSS (10-14).  
The 2016 ACR/EULAR classification criteria set for pSS was developed and validated 
using three international patient cohorts (15, 16). The set includes five weighted items: focal 
lymphocytic sialadenitis with a focus score (FS) ≥1 by LSG and presence of anti-SSA(Ro) 
antibodies are each weighted 3 and considered to be major items; whereas a positive ocular 
staining score (OSS ≥5), positive Schirmer’s test (≤5 mm/5 min), and unstimulated whole 
salivary (UWS) flow rate 0.1 mL/min each have a weight of 1. These criteria are designed to 
be applied only to patients who have subjective ocular and/or oral dryness and/or a positive 
item on the EULAR Disease Activity Index for pSS (ESSDAI) (17). A score ≥ 4 indicates 
pSS.  
However, the diagnosis and classification of pSS continue to be challenging, as many 
other conditions can produce similar presentations. Continued efforts to improve current 
criteria sets are therefore warranted to increase diagnostic accuracy and decrease time to 
diagnosis. 
Adding SGUS as a criterion has been reported to improve the performance of 
classification criteria (18). In a cohort of patients with suspected SS, adding SGUS to the 
American-European Consensus Group (AECG) criteria set increased sensitivity from 77.9% 
to 87%, and similar results were obtained with the 2016 ACR/EULAR classification criteria 
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(10, 19). Many of the patient cohorts used to develop and validate the 2016 ACR/EULAR 
criteria were initiated in the early 2000s, and none was assessed using SGUS, whose 
metrological properties were unknown at the time. Consequently, inclusion of SGUS in the 
criteria set was not possible (15, 16). However, the ACR and EULAR used a well-defined and 
established method with which they had already acquired experience when developing criteria 
for rheumatoid arthritis and scleroderma. This method assigns weights to each criterion in the 
set, thereby allowing the subsequent addition of criteria provided they are assigned the 
appropriate weights. 
The international EULAR US-pSS Task Force was created in 2012 with the objectives 
of standardizing SGUS (13, 20, 21), maximizing its usefulness in pSS, developing a reliable 
SGUS scoring system, and assessing the addition of an SGUS score to pSS classification 
criteria sets according to OMERACT and EULAR recommendations. Experts were considered 
for this task force if they worked with SS centers for excellence and were involved in active 
published research on pSS. Meetings and projects were designed each year at ACR and 
EULAR meetings to evaluate the metrological properties of SGUS (20-22), create an atlas, 
and develop a consensual score (21).The score assesses greyscale (B-mode) homogeneity 
lesions (21)for each of the four major SGs (two parotid and two submandibular glands), 
focusing on anechoic/hypoechoic foci as follows: 0, no lesions; 1, hypo/anechoic areas 
occupying less than 25% of the gland surface area; 2, hypo/anechoic areas occupying 25% to 
50% of the gland surface area; 3, hypo/anechoic areas occupying more than 50% of the gland 
surface area; and 4, hypo/anechoic areas occupying the entire gland surface area. A score ≥ 2 
is associated with Sjogren. 
The objective of the UTOPIA (Ultrasound TO diagnose and classify PrImAry Sjögren’s 
syndrome) study reported here was to evaluate the weight that should be assigned to SGUS if 
added to the 2016 ACR/EULAR pSS classification criteria set. To this end, an international 
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panel of pSS experts examined clinical vignettes. Our working hypothesis was that SGUS 
could be used in a standardized manner to evaluate patients with pSS in both daily practice 
and clinical trials. 
 
METHOD 
We used data from patients with suspected pSS to develop realistic clinical vignettes. 
Experts assessed the vignettes and determined whether they indicated probable or definitive 
pSS. Potential effects on this expert pSS diagnosis of adding SGUS findings to the available 
information were evaluated (17).  
 
Design of the vignettes 
A rheumatologist (CB) collected the main demographic data and signs of pSS from the 
Sjögren’s Clinic database at the University of Pisa, Italy (23, 24). This step considered only 
patients for whom all relevant data were available, including the 2016 ACR/EULAR 
classification criteria, systemic manifestations, and SGUS findings. Controls were patients 
referred for suspected pSS in whom a comprehensive workup did not support a diagnosis of 
pSS.  
 Concerning the vignette: Each feature was assigned a weight based on its frequency in the 
patient cohort (e.g., sex, age, parotid gland enlargement, and systemic manifestations 
including inflammatory arthritis, cytopenia, interstitial lung disease, peripheral neuropathy, 
and Raynaud’s phenomenon).  
A computer algorithm designed by one of us (FG) determined all possible combinations 
of the 2016 ACR/EULAR classification criteria (ocular and oral dryness, anti-SSA antibodies 
positive vs. negative, Schirmer’s test > vs. ≤5 mm/5 min, LSG with FS <1 vs. ≥1, UWS flow 
rate > vs. ≤0.1mL/min, and OSS <5 vs. ≥5), disease duration <3 years or ≥3 years, and 
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standardized SGUS score <2 vs. ≥2. These variables were handled in the vignette as a binary 
variable. The number of combinations was 512, and 512 vignettes were therefore created. 
Each vignette (supplementary file) provided information on the medical history 
(symptom duration, sex, age), clinical symptoms (ocular and oral dryness), and systemic 
manifestations (see above). In each vignette, the patient had subjective ocular and/or oral 
dryness or a systemic manifestation. Disease duration was given in each vignette to assess 
whether this information was significantly associated with the diagnosis made by experts.  
All the vignettes were reviewed independently by three experts (VDP, AS, DC) and 
found to be clinically plausible.   
 
Panel of experts 
Of 25 invited pSS experts, 24 participated in the study. Among them, 19 were from 12 
European countries, 3 from North America, and 2 from Japan. Only 10 were EULAR US-pSS 
Task Force members, to minimize potential bias due to a strong favorable opinion of the 
contribution of SGUS to the diagnosis of pSS within the task force. Of the 24 experts, 20 were 
rheumatologists, 3 were dentists, and 1 was a radiologist. Each expert evaluated 64 vignettes 
using a secure web-based relational database. Thus, each vignette was evaluated by 3 experts. 
The experts used four diagnostic categories to assess the vignettes: pSS definitely absent, pSS 
unlikely, pSS probable, and pSS definitely present. The vignette was considered to indicate 





Validation in the independent DiapSS cohort 
For validation of the vignette assessment findings, we used the French DiapSS cohort 
of patients with suspected pSS (18, 25). As previously described, the diagnoses in these 
patients were established by consensus among three of us (AS, SJJ, and VDP). A diagnosis of 
pSS did not require fulfillment of the 2002 AECG or 2016 ACR/EULAR classification 
criteria. For this study, we assessed the performance of the 2016 ACR/EULAR classification 
criteria with and without the SGUS score.  
Ethical Committee approved the DiapSS cohort (NCT 03681964). 
 
Statistical analysis 
The statistical analysis was performed using SAS software, version 9.4 (SAS Institute, 
Cary, NC, USA). The vignettes were divided into two groups based on whether 2 of the 3 
experts gave a diagnosis of probable or definite pSS (defined here as an expert pSS diagnosis). 
We then sought to determine which features other than the classification criteria were 
significantly associated with an expert pSS diagnosis. For each vignette, the 2016 
ACR/EULAR score was computed, and Student’s t test was then applied to compare mean 
score values between the two groups of vignettes. The chi-square test was used to compare 
the two groups of vignettes regarding the proportion of pSS diagnoses defined as a 2016 
ACR/EULAR score ≥4 and as an SGUS score ≥2. Univariate and multivariate logistic 
regression models were built to identify features (including the SGUS score value and 
established classification criteria) associated with an expert pSS diagnosis. Significance was 
assessed using Wald tests. 
To assess the weight of the SGUS score and of the 2016 ACR/EULAR criteria, we relied 
on estimated coefficients from the fitted logistic regression models. The results were then used 
to derive a modified score (ACR/EULAR + SGUS score). Cutoffs were determined by plotting 
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receiver operating characteristics (ROC) curves and computing the areas under the curve 
(AUC). Sensitivity and specificity of the 2016 ACR/EULAR score and modified 2016 
ACR/EULAR+ SGUS score for diagnosing pSS were assessed on the vignette data (learning 
sample) and DiapSS data (validation sample). The characteristics of patients in the DiapSS 
cohort were described as mean and standard deviation for continuous variables and number 
and percentage for categorical variables. 
 
RESULTS 
Assessment of the vignettes 
 Of the 512 vignettes, 366 were classified by at least 2 of the 3 experts as indicating 
probable or definite pSS, i.e., were given an expert pSS diagnosis as defined for this study. Of 
these 366 vignettes, 330 (90.2%) had a 2016 ACR/EULAR score ≥4 and 205 (56%) had an 
SGUS score ≥2. Of the 146 vignettes for which pSS was deemed absent or unlikely, 22 
(15.0%) had a 2016 ACR/EULAR score ≥4.  
 
Items associated with an expert pSS diagnosis (Table 1) 
By univariate analysis, the 2016 ACR/EULAR score and SGUS score were significantly 
associated with an expert pSS diagnosis. Multivariate analysis showed that each of these 
associations was independent (p<0.001 for all associations). Logistic regression analysis 
identified six vignette features that were significantly and independently associated with an 
expert pSS diagnosis, namely, positive anti-SSA (weight, 4), FS≥1 (weight, 4), SGUS score 
≥2 (weight, 2), positive Schirmer’s test (weight, 1), xerostomia (weight, 1), and UWS flow 
rate <0.1 mL/min (weight, 1). 
 
2016 ACR/EULAR + SGUS score: vignette evaluation  
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The results of the logistic regression analysis were then used to derive a modified score 
(ACR/EULAR + SGUS score) and discussed by the experts.  
Adding the SGUS score to the 2016 ACR/EULAR classification criteria set produced 
the following weights: positive anti-SSA, 3; FS≥1, 3; SGUS score≥2, 1; positive Schirmer’s 
test, 1; OSS ≥5, 1; and UWS flow rate ≤0.1 mL/min, 1 (Table 2). OSS was not significantly 
associated with an expert pSS diagnosis but was kept in this study because it is a 2016 
ACR/EULAR classification item. 
Figure 1 and table 3 show the ROC curve and the different cutoff. A cutoff of 4 
provided the best sensitivity 95.6 (93.0-97.5) with a specificity of 82.6 (76.0-88.0).Adding 
SGUS improve the sensitivity from 90.2 % to 95.6% with a quite similar specificity 84.1% 
versus 82.6%.  
 Specificity was highest with a cutoff of 5 (95.9 [91.3-98.5], whose sensitivity was 
81.4 (77.1-85.3). So, adding SGUS improve the sensitivity from 68.9 % to 81.4% with a 
quite similar specificity 97.3% versus  95.9%  
The AUC was better when using the 2016 ACR/EULAR set with addition of the SGUS 
(figure 1). 
The panel of experts considered that classification should not be recommended only with the 
sum of the minor criteria. So the classification with US should be considered with SGUS item 
that could substitute one of the other minor criteria with a cutoff of 4 or in addition to the other 
items with a cutoff of 5 (table 2)..  
 
Validation of the weight of SGUS versus other items of the 2016 ACR/EULAR criteria 
in an independent patient cohort 
The validation cohort was composed of 164 patients from the DiaPSS cohort. Mean age 
was 55±14 years, and 68 (41%) patients had an SGUS score ≥2 (18, 25). Of the 164 patients, 
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80 were given an expert diagnosis of pSS and 84 were not (Table 4). The SGUS score was ≥2 
in 52 (65%) patients with pSS and 16 (5%) without pSS (p<0.001). Adding SGUS increased 
sensitivity to a similar degree as in the vignette study, i.e., for the 2016 ACR/EULAR criteria 
set, from 87% to 93%; specificity decreased slightly, from 84% to 82%. 
We determined how many patients in the validation cohort had a modified 2016 
ACR/EULAR + SGUS score=4 due only to the presence of minor criteria (positive Schirmer’s 
test, 1 point; OSS≥4, 1 point; UWS flow rate <0.1 mL/min, 1 point; and SGUS score ≥2, 1 
point). No patient had an ACR/EULAR with SGUS score ≥4 without having an FS≥1 or 
positive anti-SSA antibodies. 
  
DISCUSSION 
SGUS has been shown to contribute to the classification and the diagnosis of pSS (26, 
27) and is used routinely by experts to assess patients with suspected pSS. SGUS findings 
were not included in recent classification criteria because the cohorts used to develop them 
were initiated at a time when SGUS was not yet fully developed. However, the method used 
to create these new criteria sets allows the addition of items proven to be useful. We evaluated 
whether adding SGUS findings improved the performance of the 2016 ACR-EULAR criteria 
set, to determine whether further work using the ACR-EULAR methodology is warranted to 
develop and validate a new criteria set including the SGUS (28). 
In our clinical-vignette study, an abnormal SGUS score (21) was significantly associated 
with an expert pSS diagnosis, by both univariate and multivariate analyses Adding SGUS 
improved the sensitivity of the classification criteria for detecting pSS, with little or no loss of 
specificity. To our knowledge, no other item has been shown to improve the performance of 
pSS classification criteria sets in groups of patients (29). 
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We assessed the contribution of SGUS to classify pSS patients by adding the SGUS 
score to the other criteria in the 2016 ACR/EULAR set. The results showed that an OSS≥5 
was not significantly associated with an expert pSS diagnosis. However, an OSS ≥5 
contributed to classify pSS in the 2016 ACR/EULAR criteria. A majority of experts on our 
panel felt that an OSS≥5 deserved to be kept among the classification criteria. We therefore 
kept it in the criteria set, with the same weight as the Schirmer and UWS criteria. However, 
there is a need for a new objective tool that detects ocular dryness effectively, requires only 
widely available material, and can be performed by non-ophthalmologists. 
Surprisingly, disease duration (<3 years vs. ≥3 years) was not associated with an expert 
pSS diagnosis. In previous studies, the only feature that reflected disease progression was the 
nature of the cells in the LSG biopsy (30). SGUS abnormalities have been reported to occur 
early, at the clinical onset of pSS (10).However, SGUS evidence of parenchymal 
abnormalities in patients with pSS exhibited little or no change over a 2-year period (25).  
These data support the potential usefulness of SGUS as a classification criterion for pSS. It 
would be interesting to investigate whether adding SGUS improves diagnostic performance 
in patients who have only systemic manifestations or very early pSS.  
In our vignette study, adding SGUS improved the sensitivity of ACR/EULAR 
classification criteria sets , by 5% to 10%. Specificity improved only slightly, suggesting that 
some of the experts may have lacked confidence in the SGUS score. As an expert pSS 
diagnosis was defined as at least two of the three experts considering that the vignette indicated 
probable or definite pSS, and only half the experts had experience with SGUS, an SGUS score 
≥2 may not have markedly increased the probability of an expert pSS diagnosis. In the DiaPSS 
cohort of patients with suspected pSS, the sensitivity gain obtained by adding SGUS was 
greater, while specificity non significantly decreased. A recent score derived from ours was 
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also recently defined by the OMERACT (31), and confirmed good inter and intrareliabilities 
of greyscale lesions and anechoic/hypoechoic foci using a semi quantitative evaluation. 
The 2016 ACR/EULAR classification criteria were built as weighted items and can be 
modified. Adding SGUS increases the performance of the set although 2016 ACR/EULAR 
classification criteria already had an excellent diagnostic performance (criteria AUC is 0.95 
and criteria plus SGUS AUC is 0.96). Depending on the cutoff, SGUS increase the sensitivity 
with the same specificity than the 2016 ACR/EULAR classification criteria with a cutoff of 4, 
or keep a good specificity while increasing sensitivity with a cutoff of 5. Using a cutoff of 4, 
is more easily for practitioners and SGUS item could substitute other minor items of the 
criteria, rather than being added to the others minor criteria 
One of the limitations of our study is that the various specialties involved with 
diagnosing pSS were not equally represented in the panel of experts, as 20 of the 24 experts 
were rheumatologists and 3 were oral medicine or dentistry. All are experts in Sjogren and 
participate to elaborate large cohorts of Sjögren patients and to the development of the 
2016ACR/EULAR criteria. We relied on fictitious vignettes, in a departure from the method 
used for the development and validation of the 2016 ACR-EULAR criteria set. The absence 
of a significant association between an OSS≥5 and an expert pSS diagnosis suggests that the 
absence of ophthalmologists among the panel members may have resulted in insufficient 
importance being given to the OSS. Despite these limitations, our results strongly suggest that 
the SGUS score assists in the classification of pSS and deserves inclusion in the next iteration 
of the ACR-EULAR classification criteria for pSS, which is currently being developed. 
Furthermore, our study confirms the diagnostic usefulness of SGUS in clinical practice, thus 
offering a new tool to clinicians involved in the diagnosis and management of pSS. 
In conclusion, an abnormal SGUS score was associated with an expert pSS diagnosis. 
With our study methodology, the weight of the SGUS score was similar to that of minor 
15 
criteria (UWS flow rate and Schirmer test). Adding an SGUS score ≥2 to the 2016 
ACR/EULAR classification criteria improved sensitivity without substantially modifying 
specificity when an expert pSS diagnosis was used as the reference standard. The next step 
will be to formally re-evaluate the 2016 ACR/EULAR criteria set with the SGUS score in 
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